<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In the STOP II trial, discontinuation of prophylactic transfusions in high risk children with <z:e sem="disease" ids="C0002895" disease_type="Disease or Syndrome" abbrv="">sickle cell disease</z:e> (SCD) resulted in a high rate of reversion to <z:mp ids='MP_0000233'>abnormal blood-flow velocities</z:mp> on transcranial Doppler (TCD) ultrasonography and <z:hpo ids='HP_0001297'>strokes</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We analyzed data from STOP II to determine the effect of discontinuing transfusions on the development or progression of silent brain <z:mpath ids='MPATH_124'>infarcts</z:mpath> on magnetic resonance imaging (MRI) </plain></SENT>
<SENT sid="2" pm="."><plain>At study entry, 21 of 79 (27%) patients had evidence of silent <z:mpath ids='MPATH_124'>infarcts</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>There were no statistically significant differences in baseline characteristics between patients with <z:mpath ids='MPATH_458'>normal</z:mpath> brain MRI or silent <z:mpath ids='MPATH_124'>infarcts</z:mpath> at study entry </plain></SENT>
<SENT sid="4" pm="."><plain>At study end, 3 of 37 (8.1%) patients in the continued-transfusion group developed new brain MRI lesions compared with 11 of 40 (27.5%) in the transfusion-halted group (P = .03) </plain></SENT>
<SENT sid="5" pm="."><plain>The total number of lesions remained essentially unchanged decreasing from 25 to 24 in the continued-transfusion group while increasing from 27 to 45 in transfusion-halted patients </plain></SENT>
<SENT sid="6" pm="."><plain>Thus, discontinuation of transfusions in children with SCD and abnormal TCD who revert to low-risk increases the risk of silent <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Together with data from STOP, these findings demonstrate that transfusions prevent the development of silent <z:mpath ids='MPATH_124'>infarcts</z:mpath> in patients with SCD and abnormal TCD but <z:mpath ids='MPATH_458'>normal</z:mpath> MRA </plain></SENT>
</text></document>